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Complications of allogeneic hematopoietic stem cell transplantation (HSCT) have been 
attributed to immune cells transferred into the patient with the graft. However, a detailed 
immune cell composition of the graft is usually not evaluated. In the present study, we 
determined the level of variation in the composition of immune cells between clinical 
HSCT grafts and whether this variation is associated with clinical outcome. Sizes of 
major immune cell populations in 50 clinical grafts from a single HSCT Centre were 
analyzed using flow cytometry. A statistical comparison between cell levels and clinical 
outcomes of HSCT was performed. Overall survival, acute graft-versus-host disease 
(aGVHD), chronic graft-versus-host disease (cGVHD), and relapse were used as the pri-
mary endpoints. Individual HSCT grafts showed considerable variation in their numbers 
of immune cell populations, including CD123+ dendritic cells and CD34+ cells, which 
may play a role in GVHD. Acute myeloid leukemia (AML) patients who developed aGVHD 
were transplanted with higher levels of effector CD3+ T, CD19+ B, and CD123+ dendritic 
cells than AML patients without aGVHD, whereas grafts with a high CD34+ content 
protected against aGVHD. AML patients with cGVHD had received grafts with a lower 
level of monocytes and a higher level of CD34+ cells than those without cGVHD. There 
is considerable variation in the levels of immune cell populations between HSCT grafts, 
and this variation is associated with outcomes of HSCT in AML patients. A detailed 
analysis of the immune cell content of the graft can be used in risk assessment of HSCT.
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inTrODUcTiOn
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established and often the only cura-
tive treatment for many malignant hematological diseases. Allogeneic HSCT grafts are harvested 
from bone marrow (BM) or from peripheral blood (PB) after HSC mobilization and transplanted 
to the patient in order to reconstitute hematopoiesis and the immune system with the donor’s cells 
and to immunologically kill the recipient’s residual cells. Graft-versus-host disease (GVHD) is a 
severe complication of allogenic HSCT in which the donor’s immune cells recognize the patient’s 
tissues as foreign and destroy epithelial and in some cases also endothelial cells. The acute form of 
TaBle 1 | The demographic data of the 50 patients and the 50 hscTs included in the study.
Disease Frequency gender 
F/M
Median age  
(x–y)
graft source  
BM/PB
conditioning  
ric/Mac (seq.)
is  
cni/mtor
agVhD/grades 
3–4
cgVhD  
yes/no (ne)
relapse cMV alive 
9/2015
ALL 6 5/1 32 (19–66) 1/5 1/5 4/2 3/0 2/3 (1) 1 3 5
AML 23 10/13 57 (29–68) 5/18 10/8 (5) 6/16a 13/6 7/12 (4) 4 12 15
CLL 3 1/2 61 (58–61) 0/3 2/1 1/2 3/2 2/1 0 1 3
MDS 3 1/2 60 (58–63) 1/2 2/1 1/2 1/1 2/1 0 2 2
MF 1 1/0 51 0/1 1/0 0/1 1/1 (1) 1 1 0
MM 7 4/3 55 (43–62) 0/7 3/4 2/5 5/4 5/2 0 5 5
MPN 1 0/1 43 0/1 0/1 0/1 0 (1) 1 1 0
SAA 3 3/0 55 (22–63) 3 4/0 3/1 3/0 1/2 1 1 2
MbH 1 0/1 43 0/1 0/1 0/1 0 0/1 0 0 1
NHL 1 0/1 24 0/1 1/0 0/1 0 1/0 1 0 0
T-LBL 1 0/1 64 0/1 0/1 0/1 1/1 1/0 1 0 0
Total 50 25/25 55 (19–68) 10/40 24/21 (5) 17/33 30/15 21/22 (7) 9 26 33
Patient hematological malignancies varied a lot. Primary diseases were acute myelogenous (AML) and lymphoblastic leukemia (ALL), chronic lymphoblastic (CML) and 
myelomonocytic (MM) leukemia, myelodysblastic syndrome (MDS), myelofibrosis (MF), myeloproliferative neoplasms (MPN), severe aplastic anemia (SAA), Hodgkin (MbH) and  
non-Hodgkin lymphomas (NHL), and T-cell lymphoblastic lymphoma (T-LBL).
ne, not evaluable.
aOne patient received steroid treatment.
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GVHD (aGVHD) normally occurs within the first 100 days after 
engraftment, whereas symptoms of chronic GVHD (cGVHD) 
appear later (1, 2). The pathogenesis of GVHD involves complex 
interactions of cytokines and immune cells; however, the exact 
mechanism is not completely understood (2–5). The donor’s 
alloreactive effector T cells and the host’s antigen-presenting 
cells (APCs), such as dendritic cells, have been shown to have 
an essential role in the initiation of GVHD. Depletion of effector 
T cells from the HSCT graft decreases the risk of GVHD but at the 
same time increases the relapse rate, obviously due to insufficient 
graft-versus-leukemia (GVL) effect (2, 4–6).
Studies performed mostly on animal models have demon-
strated the role of donor’s immune cells in more detail (5, 7–10). 
Effector T cells, in particular alloreactive CD8+ T cells, of the 
graft are known to have a crucial, direct role in the pathogenesis 
of GVHD (5, 11). As well as the dose of regulatory T cells (12–14), 
the balance between the Th1 and Th2 subsets of T cells is thought 
to be critical in prevention and control of the intensity of GVHD 
(5, 15). Matte et al. showed that the donor’s APCs are required 
for GVHD but not for the GVL effect (16). Furthermore, a high 
number of B cells in the graft have been reported to associate with 
the aGVHD risk. B cells most likely present antigens to T cells 
and secrete activating cytokines (17, 18), whereas monocytes and 
invariant NKT cells are thought to have an anti-GVHD effect 
(8, 9). The dose per patient kilogram of CD34+ hematopoietic 
progenitor cells is applied in clinical practice as a high dose of 
CD34+ cells is often reported to lead to a better hematopoietic 
recovery and transplantation outcome, although also conflicting 
effects are reported and there are contradictory suggestions as an 
optimal CD34+ dose (19–22). At least in some donor-recipient 
combinations, natural killer (NK) cells are effective in killing 
remaining malignant cells and hence decrease the risk of relapse 
(23–25).
The immune cell composition of the graft is typically not char-
acterized in clinical practice, except for the numbers of CD34+ 
and CD3+ cells. Obviously, there is a high level of variation in 
the cellular composition of the grafts, depending on the donor’s 
background and stem cell collection methods and source (11), 
although only a few systematic, modern studies have been pub-
lished (26). To address this question, we analyzed variation in the 
levels of immune cell populations in 50 clinical HSCT grafts and 
its impact on the outcome of allogenic HSCT.
MaTerials anD MeThODs
Patients
Altogether, 73 allogeneic HSCTs were performed for adult 
patients in the Turku Central Hospital Hematology Ward and 
Stem Cell Transplantation Unit during the study period between 
February 2014 and February 2015. For the present study, we were 
able to get fresh samples of sufficient size from 50 grafts.
The demographic data of the 50 patients and the 50 HSCTs 
carried out on them are shown in Table  1. It is of note that 
one patient, in fact, received two HSCTs, only the first of which 
was included in the present study. A 46/50 (94%) patients 
received a 10–12/12 HLA-matched transplants. Nine (18%) 
patients received a graft from a related donor and 39 patients 
(78%) from a matched unrelated donor. Two patients (4%) were 
transplanted with a graft from a haploidentical (6/12 matched) 
family donor.
Informed consent was obtained from all patients, and the 
study protocol was approved by the local Ethical Review Board 
of the Turku University Hospital, Turku, Finland.
clinical Protocols, Data, and endpoints
The patients were treated with the standard clinical protocols. 
They were pre-conditioned by using myeloablative chemother-
apy (MAC), reduced-intensity conditioning (RIC), or sequen-
tial use of intensive chemotherapy (SEQ). The MAC regimen 
consisted of fludarabine 30 mg/m2/day for 5 days and busulfan 
3.2 mg/kg/day intravenously for 3–4 days, or, for patients with 
TaBle 2 | immune cell subpopulations and their surface markers.
immune cell subsets Definition
Hematopoietic cells CD45+
B cells CD45+, CD19+
Myeloid dendritic cells CD45+, CD11c+, CD19−, CD123−
Plasmacytoid dendritic cells CD45+, CD11c−, CD19−, CD123+
CD34+ progenitor cells CD45+, CD34+
CD3+ T cells CD45+, CD3+
CD8+ T cells CD45+, CD3+, CD4−, CD8+
CD4+ T cells CD45+, CD3+, CD4+, CD8−
CD25+ T cells CD45+, CD3+, CD4+, CD8−, CD25+
CD3− cells CD45+, CD3−
Natural killer cells CD45+, CD3−, CD16+, CD56+
Lymphocytes FSC, SSC, CD45+, CD3+
Monocytes FSC, SSC, CD45+
Immune cell subpopulations were identified using combinations of fluorochrome-
labeled antibodies. Cell populations were gated based on their combination of cell 
surface markers, cell size, and granularity.
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ALL, cyclophosphamide 60 mg/kg/day for 2 days, followed by 
fractionated total body irradiation 12  Gy. The RIC regimen 
consisted of fludarabine 30 mg/m2/day for 5 days and busulfan 
3.2  mg/kg/day intravenously for 2  days. The SEQ condition-
ing included fludarabine-high dose sytarabine-idarubicine 
induction, followed by conditioning with cyclophosphamide 
60 mg/kg/day for 2 days and total body irradiation 4 Gy. Rabbit 
antithymocyte globulin at a dose of 2.5  mg/kg/day for 2  days 
together with tacrolimus or everolimus and a short course of 
methotrexate were used for GVHD prophylaxis.
Clinical data were collected routinely and included in the 
study during the surveillance period until the end of September 
2015. The median follow-up period was 12  months (range 
7–19  months). GVHD was defined as either acute (Seattle-
Glucksberg criteria) (27) or chronic according to the standard 
criteria and on the basis of the 100-day onset limit, unless the 
patient had characteristic symptoms of acute GVHD after day 
100 (late onset aGVHD).
Acute GVHD was graded from none or mild (grades 0–1) 
to severe/life-threatening GVHD (grades 2–4) according to 
Przepiorka et al. (27). Chronic GVHD was classified for statistical 
analysis as yes or no.
Patient chimerism was tested monthly from whole blood and 
from the blood T-cell fraction during the post-transplant period 
and from the BM CD34+ precursor cell fraction at 2- to 3-month 
intervals by highly sensitive Abbott AlleleSEQR chimerism assay. 
Serum cytomegalovirus was monitored weekly during the first 
6 months by qPCR.
hscT graft samples
An aliquot of 3–4  ml was taken from allogeneic HSCT grafts 
before infusion. The fresh sample was transported to the FRC 
Blood Service and analyzed within 12  h. Briefly, sample was 
diluted 1:1 in PBS-EDTA (Invitrogen) supplemented with 2% 
(V/V) fetal bovine serum (Gibco), overlaid onto Ficoll-Paque 
PLUS (GE Healthcare) density gradient medium, and centrifuged 
in a SepMateTM-15 tube (StemCell Technologies) according to 
the manufacturer’s instructions. The mononuclear cell (MNCs) 
fraction, buffy coat, was collected and analyzed. Cell viability and 
the total number of cells were calculated with NucleoCounter 
before further analysis.
Flow cytometric analysis
Relative proportions of each cell populations in the aliquot of 
graft sample were analyzed using flow cytometry [FACSAria IIu, 
Becton Dickinson (BD)] independently at the Finnish Red Cross 
Blood Service as part of the present study. Cell populations of dif-
ferent main immune cell populations and CD34+ hematopoietic 
progenitor cells (hereafter “CD34+ relat”) were identified using 
combinations of fluorochrome-labeled antibodies (see Table 2). 
Percent amount of each cell population was calculated as a pro-
portion out of CD45+ cells. Average proportions of lymphocyte 
and monocyte cell populations were estimated and gated based 
on their size and granularity.
Antibody-fluorochrome combinations included CD45-PerCp-
Cyanine 5.5, CD3-FITC, CD4-APC-eFluor780, CD11c-APC, 
CD16-PE, CD19-FITC, CD25-BV421, CD34-PE, CD56-APC (all 
from eBiosciences), and CD123-BV421 and CD25-BV421 (Becton 
Dickinson). Conjugated isotype controls (eBiosciences) and 
unlabeled cells were used as negative controls. BD Compensation 
beads were used for signal compensations. Instrument settings 
and performance were checked using BD’s CST Protocol. The 
FACSDiva™ Flow Cytometry Software Version 5.02 and FlowJO 
7.0 were used for data analysis.
The total number of CD34+ cells in the entire volume of the 
collected graft (hereafter “CD34+ tot”) was measured in the 
stem cell collecting centers during harvesting of the graft. In 
our sample, cohort the median total, number of CD34+ cells 
was 1.48 × 108 cells/l in BM- and 5.82 × 108 cells/l in PB-derived 
grafts. The total number of CD34+ cells × 108/l was used for the 
determination of clinical dose (CD34+ dose, number of CD34+ 
cells per recipient weight).
colony Forming Unit assay
The Colony Forming Unit (CFU) assay estimates the number and 
potency of hematopoietic progenitors. The assay was performed 
according to the manufacturer’s instructions (MethoCult™ 
Media, StemCell Technologies). Cell colonies were counted on 
days 13 and 18, and triplicates were used in calculations.
statistical analysis
Statistical tests on associations between levels of cell populations 
in grafts and clinical endpoints were mainly carried out using 
Wilcoxon rank-sum test and Fisher’s exact test, and other tests as 
described in the text. As multivariate analysis was not meaningful 
due to low numbers of cases in some groups, we instead used 
random forest classifiers to assess how well the clinical endpoints 
could be predicted using the measured cell populations while also 
including other possibly influencing factors. R and caret package 
(28–30) were used for statistical analyses. All cell populations, as 
well as HLA match, graft type, immunosuppressive medication, 
pre-conditioning, and donor type, were used as potential predic-
tors, and the accuracies were estimated using fourfold cross-
validation repeated 100 times. Within each clinical endpoint, 
4Impola et al. Immune Cell Composition
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we ranked (from 0 to 100) the importance of the parameter as 
a predictor. These rankings were used along with the nominal 
p-values to estimate the significance of the findings. It is of note 
that the results are based on a limited set of data points and the 
classifiers have not been tested with real held-out dataset, so the 
reported performances (Table S1 in Supplementary Material) 
may be over-optimistic.
resUlTs
clinical Outcomes
The demographic data of the patients are summarized in Table 1. 
During the study period, 17 of the 50 patients died (overall sur-
vival 66%, transplantation related mortality 24%). Patients who 
received stem cell graft from an HLA-matched sibling donor had 
a better overall survival than those who received an unrelated 
HSCT (p = 0.039). No other statistically significant association 
was found between clinical endpoints and the donor type. The 
HLA match showed no statistically significant association with 
clinical endpoints (data not shown).
Acute GVHD was diagnosed in 30 of the 50 patients (60%), 15 
of whom had severe grades 3–4 aGVHD while 15 had grades 1–2 
aGVHD. Chronic GVHD was classified as yes/no, and even very 
mild symptoms were included to the positive group. This might 
explain rather high incidence of cGVHD among our patients as 
twenty-one (42%) had cGVHD. Nine of the 50 patients (18%) had 
a relapse during the surveillance period. Serum cytomegalovirus 
was found in 26 of the 50 patients (52%).
Variation between BM and PB grafts
The grafts originated from BM in 10 HSCTs (20%) and from PB 
in 40 HSCTs (80%). We compared the differences in the propor-
tional shares, i.e., not absolute numbers, of immune cell popula-
tions between these two types of grafts (Figure 1A). BM-derived 
grafts contained higher levels of lymphocytes (p = 0.008), CD34+ 
cells (p =  4.3 ×  10−6), and CD19+ B cells (p =  0.009) than the 
PB-derived grafts. PB-derived grafts had a significantly higher 
level of monocytes (p =  2.4 ×  10−10) than the BM grafts. The 
graft type as such was not found to be associated with the clinical 
endpoints.
Variation between individual grafts
The levels of immune cell subpopulations varied between 
individual stem cell grafts (Figures  1B–D). Figure  1B shows 
the variation of all cell populations, and Figure  1C shows the 
variation in the effector subsets of CD3+ cells and in NK cells. 
Figure 1D shows the change in the levels of B cells, CD34+ cells, 
and two types of dendritic cells (CD11+ and CD123+ cells). The 
levels of many cell populations known to be relevant to the out-
come of HSCT showed variation between the grafts. The highest 
coefficients of variation (variability in relation to the mean of the 
measurement) were seen for the levels of CD34+ progenitor cells, 
CD123+ plasmacytoid and CD11c+ myeloid dendritic cells, and 
CD19+ B cells. On the other hand, CD4+ and CD8+ T-cell popula-
tions had low coefficients of variation (data not shown).
association of Variation in the graft cell 
Populations with clinical endpoints
Association analyses between the clinical endpoints and levels 
of immune cells in the grafts were performed. As multivariant 
analysis was not meaningful due to low numbers of cases in some 
groups, we instead used random forest classifiers to assess how 
well the clinical endpoints could be predicted using the measured 
cell populations while also including other possibly influencing 
factors. Hence, classifiers were built to find how important each 
cell population is for predicting clinical outcomes. The best clas-
sification accuracies were obtained in Acute myeloid leukemia 
(AML) cases for cGVHD (AUC 0.86), relapse (AUC 0.81), and 
aGVHD (AUC 0.78).
When all diagnoses were included, none of the classifiers 
achieved a very high performance (maximum AUC 0.73), pos-
sibly indicating high heterogeneity in the diseases. All results are 
summarized in Table S1 in Supplementary Material.
When all HSCTs were included, a low “CD34+ tot” level in the 
graft was associated with the cytomegalovirus positivity (Figure 2; 
p = 0.04). In addition, an association was observed between a low 
level of “CD34+ relat” and the occurrence of cGVHD (p = 0.022) 
among the patients (N =  10) who received a BM graft. A low 
level of CD25+ CD4+ T cells, a population containing regulatory 
T cells, was associated with the occurrence of relapse (p = 0.041) 
and rejection (p = 0.032) (data not shown).
To reduce heterogeneity of the patient group, we analyzed 
the largest single patient group, AML, separately (N = 23 of the 
50 patients). A low “CD34+ tot” level in the graft (Figure  3A; 
p = 0.014) and a low CD34+ dose (cells/kg; Figure 3B; p = 0.015) 
were both associated with the occurrence of aGVHD in the AML 
patients. The association remained statistically significant regard-
less of conditioning (data not shown).
Acute myeloid leukemia patients with grades 2–4 aGVHD 
had received grafts with higher levels of CD3+ T lymphocytes 
than those without aGVHD (Figure  4A; p =  0.007). In fact, 
there was a clear trend between the levels of CD3+ cells and 
the severity of aGVHD (Figure 4B; p = 0.028; Kruskal–Wallis 
test). Occurrence of grades 2–4 aGVHD in AML patients was 
associated with high levels of many effector immune cells 
in the graft: CD4+ cells (Figure  4C; p =  0.039), CD8+ cells 
(Figure  4D; p =  0.032), CD19+ cells (Figure  4E; p =  0.044), 
and CD123+ (Figure  4F; p  =  0.011). Of these, particularly 
CD8+ and CD123+ ranked high as predictors, attesting to the 
prominence of their role.
Acute myeloid leukemia patients with cGVHD had received 
HSCT grafts containing lower levels of monocytes (Figure 5A; 
p  =  0.005) and higher levels of “CD34+relat” (Figure  5B; 
p = 0.01) than those without cGVHD. Monocytes were ranked 
as the most important predictor for cGVHD, indicating that they 
play a major role.
DiscUssiOn
Graft-versus-host disease remains a major challenge in allogeneic 
HSCT. The mechanism of GVHD is complex and depends on 
many factors, particularly on the interactions of various immune 
FigUre 1 | Variation of immune cell subpopulations in hscT grafts. The composition of immune cell populations varied (a) among BM and PB grafts and (B) 
in individual 50 clinical HSCT grafts as measured by the percentages of the cell populations in graft samples. (c) Levels of CD3+, CD4+, CD8+, CD4+ CD25+, CD16+ 
CD56+ cell subpopulations and (D) CD19+, CD34+, CD11c+, and CD123+ cell subpopulations in each HSCT graft (N = 50) were estimated as percentages out of 
CD45+ cells. Lymphocytes and monocytes were identified based on their size and granularity.
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cell populations and on the donor’s T cells that are transferred 
along with the allograft and which attack host tissues (5). Hence, 
it is plausible that the composition of immune cells in the clinical 
HSCT graft also influence the outcome. However, current clinical 
HSCT protocols usually rely on counting from the graft only the 
numbers of nucleated cells and CD34+ hematopoietic stem cells, 
FigUre 3 | association of cD34+ cell levels in the hscT grafts with agVhD among aMl patients. AML patients with grades 2–4 aGVHD had received 
HSCT grafts (a), which contained a lower total number of CD34+ cells (p = 0.014) and (B) a lower dose of CD34+ cells/kg (p = 0.015) than AML patients with grade 
1 or no aGVHD. The median dose of CD34+ cells/kg of recipient was 5.7 × 106/kg.
FigUre 2 | association of cD34+ cell numbers in the hscT grafts with 
serum cytomegalovirus. Patients (N = 26) with serum cytomegalovirus had 
received HSCT grafts that contained lower total number of CD34+ cells 
(CD34+ tot, median 5.3 × 108/l) than those with no detected cytomegalovirus 
(N = 24) p = 0.04.
6
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with estimates of CD3+ T lymphocytes sometimes included. No 
detailed analysis of cellular content of the graft is performed. 
To address the role of immune cell composition of the graft, in 
more detail, we studied systematically 50 clinical HSCT grafts for 
their immune cell composition and its influence on the clinical 
outcome of HSCT.
First, we found that there was considerable variation between 
individual grafts in regard to levels of many cell populations that, 
based on models of GVHD pathogenesis (3, 5, 10, 31), can be 
assumed to influence the clinical outcome of HSCT, such as the 
severity of GVHD or incidence of relapse. Second, we present 
evidence that this variation in levels of certain cell populations, 
in particular levels of effector immune cells, is significantly 
associated with the grade and type of GVHD. The effect was 
clearer in a subgroup of patients, those with AML, suggesting 
that the underlying disease and its treatment should be taken 
into account.
There are only a few recent publications (11, 26, 32, 33) 
describing systematically variation in the levels of immune 
cell populations in clinical HSCT grafts. Many studies have 
concentrated on the effects of stem cell mobilizing regimens on 
immune cell levels. In these studies, differences were reported 
in the numbers of T lymphocytes and their Th1/Th2 balance 
(34) and NK cells and dendritic cells (11, 35, 36). Recent studies 
(9, 37) found that mobilization induced particular subpopula-
tions of monocytes that may regulate GVHD. In our present 
study, we observed the highest levels of variation in CD34+ 
hematopoietic cells, CD123+ plasmacytoid and CD11c+ myeloid 
dendritic cells, CD19+ B cells, and CD4+CD25+ T cells; all these 
cell populations can be assumed to play a role in GVHD, GVL, 
or relapse. As an example, the levels of CD11+ positive dendritic 
cells differed up to 10-fold between individual grafts. As rela-
tively small numbers of dendritic cells can activate the immune 
response by presenting peptide antigens to naïve T  cells, the 
differences observed here could be immunologically relevant 
(38, 39).
Only a few studies have directly addressed the origin of 
variation in immune cell numbers. It is obviously possible that 
genetic factors, such as HLA genes or interleukin-2 receptor 
A gene, determine the size of at least some immune and blood 
cell populations as reported by e.g., Orrú et  al. (40). Orrú 
et  al. concluded that heritability accounted for up to 87% of 
the variation in immune cell levels (40). However, Brodin et al. 
reported (41) based on a twin study that in fact, non-heritable 
factors, such as immunological history and vaccinations, were 
the major drivers of variation in the human immune system. 
How much these studies can be extended to clinical HSCT 
grafts is unclear.
The origin of the HSCT graft, BM versus PB is an obvious 
source of variation in cell content. PB has become widely used as 
a stem cell source, almost replacing the use of BM in allogeneic 
HSCT in some centers (35). In the present study, 20% of the grafts 
7Impola et al. Immune Cell Composition
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originated from BM and the rest were harvested from mobilized 
PB. The PB-derived grafts had a significantly higher level of 
monocytes than BM-derived grafts; this finding is in line with 
those by Korbling and Freireich (35) and Ottinger et al. (42). The 
BM-derived grafts of the present study contained higher levels of 
lymphocytes, CD19+ B cells, and CD34+ cells. The higher level of 
CD34+ cells in BM has been established earlier (43), whereas B 
cells have been reported to be more frequent in PB than in BM 
(43, 44).
The variation in the cell levels between the grafts was found 
to influence the clinical outcome of HSCT. It is of interest that 
the highest level of variation in the present study was seen in the 
FigUre 4 | association of the graft proportions of cD3+ lymphocytes, cD19+ and cD123+ cells with acute gVhD in aMl patients. (a) AML patients 
with grades 2–4 aGVHD had received grafts with higher levels of CD3+ cells than patients with grade 1 or no aGVHD (p = 0.007). (B) Patients with AML showed a 
trend (p = 0.028, Kruskal–Wallis test) toward more severe aGVHD along with the increasing levels of CD3+ cells in the graft. AML patients with grades 2–4 aGVHD 
had received HSCT grafts with higher levels of (c) CD4+, (D) CD8+, (e) CD19+, and (F) CD123+ cells as compared to those with grade 1 or no aGvHD. All 
proportions are calculated as %/CD45+ cells.
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FigUre 5 | association of monocyte and cD34+ cell levels in the hscT grafts with chronic gVhD in aMl patients. (a) AML patients with cGVHD had 
received HSCT grafts with lower levels of monocytes than AML patients without cGvHD (p = 0.005). (B) AML patients with cGVHD had received HSCT grafts with 
higher levels of CD34+ cells than those without cGVHD (p = 0.01).
number of CD34+ hematopoietic cells, the very same popula-
tion that appears to be one of the major determinants of the 
outcome of HSCT. The median total number of CD34+ cells in 
BM grafts was in the present study about fourfold lower than that 
in PB-derived grafts. However, the relative proportion of CD34+ 
cells in BM samples was clearly higher compared to PB grafts. 
We found that high levels of CD34+ cells in the graft protected 
from severe aGVHD but predisposed to cGVHD in AML patients 
and protected from serum cytomegalovirus in all patients. A high 
dose of CD34+ cells has been reported to lead to a better hemat-
opoietic recovery, however not always to a better transplantation 
outcome (19, 20, 22) Conflicting data is presented also in other 
studies (21, 45). Our finding that a high CD34+ cell content in the 
graft predisposed to cGVHD may be related to CD34+-derived 
dendritic cells that have been reported to be able to augment 
antigen presentation to donor T cells and induce cGVHD (46). 
It is of note that according to a recent study by Martin et al. (47), 
estimates of the total number of nucleated cells, especially CD34 
negative cells, might in fact be better predictors of HSCT outcome 
than the CD34+ cell dose at least in HSCT performed using RIC 
and PB.
Another major finding in the present study was the asso-
ciation of high levels of many effector cell populations, such as 
CD3+, CD4+, and CD8+ T cells or CD19+ B cells, in the HSCT 
grafts with the more severe aGVHD in AML patients. In addi-
tion, AML patients with severe aGVHD had received higher 
levels of plasmacytoid CD123+ dendritic cells (pDCs) in the 
grafts than those without or with grade 1 aGVHD. The associa-
tion of high levels of effector cell populations with more severe 
aGVHD is not surprising as it is assumed that many effector cell 
populations of donor-origin are involved in the pathogenesis 
of aGVHD (1, 5, 15). There is an abundance of evidence on the 
role of T cells as initiators of aGVHD. Also, as mediators of 
antitumor immunity, CD8+ cells, when present in high doses, 
are known to be associated with a lower risk for relapse (48), 
but we could not verify this in the present study. High regulatory 
T cell doses are known to control GVHD while still allowing 
active GVL effect (12, 13, 49, 50). We found some evidence 
indicating that low doses of CD4+ CD25+ T cells, a population 
including regulatory T cells, were associated with higher risks 
for relapse and rejection.
The possible role of pDCs in inducing aGVHD is interesting, 
but so far these cells have not been studied extensively in this 
context (26, 51). pDCs constitute a multifunctional cell type 
involved e.g., in production of type-I interferons against virus 
infections, induction of Th17 cell response, and presentation of 
peptide antigens by MHC class II to T cells (52). High levels of 
pDCs in the graft can lead to immune activation as pDCs may 
more readily detect, via their toll-like receptors, the tissue dam-
age caused by pre-transplantation conditioning. Then, they may 
become activated and act as APC. However, experimental data 
for this is still scarce (51, 53). Peric et al. recently reported that 
high levels of pDCs post-HSCT predicted good clinical outcome 
with less severe GVHD and better overall survival (53). Waller 
and coworkers (26) found that survival was better in HSCTs with 
high pDCs. More research on the role of pDCs in GVHD is clearly 
warranted.
Clinical presentation of cGVHD resembles fibrotic autoim-
mune disorders and involves Th2 and B cells (54), cytokines 
secreted by Th1 cells (55), Th17 cells, and autoantibodies (54). 
Also, a low number of active regulatory T cells (56) have pre-
viously been associated with cGVHD. The levels of regulatory 
T cells or B cells in the graft were not associated with cGVHD in 
the present study. However, we found that low levels of CD34+ 
cells and monocytes in the graft were associated with cGVHD 
in AML patients. The CD34+ and monocyte populations can 
be regarded as a source of dendritic cells (57), which can effi-
ciently present antigens to donor T cells and may, therefore, be 
involved in the induction of cGVHD. Our finding that various 
cell populations in the grafts were found to be associated with 
the development of aGVHD, as opposed to cGVHD, supports 
distinct immunological background and pathogenesis between 
the two types of GVHD.
The present study demonstrates a considerable variation 
of the cellular content in the HSCT graft which might affect 
patient outcome depending on their diagnosis. In addition to 
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